_edited.png)
RISK CONCERN
Investment Strategy, Risk Analysis, and Insights by Chartered Professionals
CUTR
Primary Facts
Medical Devices
Name:
-
Sector:
- 29925.00K
Industry:
46.61
CEO:
Mr. David Mowry
Total Employees:
Small Cap
Our Technological Advancement Rating
Our Rating:
-0.465287178
-3.390958331
Cutera, Inc. (XNAS:CUTR) In-Depth Stock/Fundamental/Options Analysis Today
Primary Targets/Price Insights
Previous Close ($) :
CUTERA, INC. (XNAS:CUTR)
One Month Price Target:
Six Month Price Target :
$47.09
Likely Price in One Year's Time:
Ticker:
$49.49
Likely Trading Range Today Under (Normal Volatility)
$47.01
Price Upper limit ($) :
$52.37
Price Lower limit ($) :
Crash Risk Prep/Key Price Levels (High Volatility/Risk)
Price, as per data analysis, isn't likely to fall below:
Today:
P490
This week:
$42.54
This month :
$37.51
Other Primary facts
Market Cap:
19.58M
Market Cap Classification:
894.40M
Number of Shares
IPO Date:
D
Best/Worst Daily Performance (Last 3+ Years)
Highest Daily Appreciation:
-24.93%
$28.41
Worst Daily Decline:
Our Options Trading Entry Points
Iron Condor entry points for options expiring in 1 week's time
Low risk (<2%) entry points
Buy Call:
Sell Call:
Buy Put:
Sell Put:
$56.77
20.41%
$36.45
$65.49
Medium risk (<10%) entry points
Buy Call
Sell Call
$52.07
Buy Put:
Sell Put:
$27.73
$41.15
$53.93
These entry points can be used for other strategies, such as butterflies, straddles, etc.
Risk-Adjusted returns (Sharpe Ratio) of
Medical Devices
Sharpe Ratio:
CUTR, is amongst the top 20% highest yielding stocks in terms of daily returns
Comparison:
1.51%
0.881741805
Sharpe ratio is 88.17% higher than the industry
Average Returns/Yield of
Medical Devices
Daily returns:
1
Weekly returns:
0.13%
Monthly returns:
0.66%
Yearly returns:
31.65%
Comparison of returns:
1.060762602
Classification:
Average annual returns/yield (last 3 years) is 106.08% above industry average
Results of T-Test of Returns:
CUTR is a riskier investment compared to Nasdaq (IXIC)
Statistical test of Returns:
0.47
Volatility (measured by Standard Deviation)
Daily Volatility:
& ratio is 25.05% higher than the market/S&P 500 average
Weekly Volatility:
4.32%
Monthly Volatility:
9.65%
Yearly Volatility:
19.30%
Volitlilty of last five days (Measured by Standard Deviation)
Average Volatility of this Week:
84.14%
-70.33%
Value at Risk Analysis (VaR)
Daily VaR:
Volatility in last five trading days has been -70.33% below long-term volatility
Weekly VaR:
-8.73%
Monthly VaR:
-19.53%
How Much Can the price of
Medical Devices
Decline in a Recession?
Likely price decline in a recession:
Base case (decline):
Risk of crash in next 6/12 months: Very high (>70%)
Worst case (decline):
$31.22
This translates to price declining to:
-33%
This translates to price declining to:
>85%
Severe Crash Probability
-39.05%
What is Value at Risk (VaR)?
Risk Fundamentals
136.14%
CUTR is a 175.63% riskier investment compared to the market/S&P 500 & is 136.14% riskier than Nasdaq (IXIC)
CUTR is a 175.63% riskier investment compared to the market/S&P 500
Beta Examination of
Medical Devices
1.840
Expected beta in 1 year's time:
0.679
Expected beta in 3 year's time:
0.962
Unlevered (debt free) Beta:
Beta in relation to market/S&P 500--1.84
Beta in relation to Nasdaq (XNAS):
Returns are, approximately, symmetrical
Beta in relation to all global stocks::
Beta is 72.84% above industry average
Beta Comparison & Analysis
Beta of competitors/peers::
0.383
0.585
Average Industry Beta:
Beta is 58.46% higher than peers
0.728366281
Sustainable Growth Rate Analysis
Sustainable growth rate for this stock/firm:
WACC is 0.59% above industry mean WACC
21.32%
Alpha provided | Alpha Analysis
Alpha provided:
1.360
2.234
10.116
Analysis of Cost of Capital of
Medical Devices
Equity cost of capital:
Alpha is 1012% higher than market/& is unsustainably high
0.509
Unlevered (without debt) cost of capital:
Equity cost of capital is 50.87% above industry mean WACC
Before-tax cost of debt:
3.28%
After-tax cost of debt:
2.07%
Overall debt rating:
1.63%
Weighted average cost of capital (WACC):
2.07%
0.59%
Key Per-Share Metrics & Analysis
Revenue per share:
-
Revenue growth rate per share of (3Y):
Price to sales ratio is -59.09% below the industry mean
-97.57%
EPS:
-
Expected Annual growth rate of EPS (3Y):
-
-
Free cash flow (FCF) per share:
Price to book ratio is 146.59% above the industry mean
Growth rate in R&D investment/expenditure is -38683.63% lower than the industry
-
Debt per share
Debt repayment rate in last quarter: 0.10%
EBITDA per share
Each employee generates -340% less EBITDA than industry average revenue per employee
Valuation Analysis Today of
Medical Devices
P/E Ratio:
Sustainable growth rate is 21.32% above industry average
P/E Ratio of Competitors/Peers:
1661.64
5.822713172
-192.4009345
-1.242254541
-
-
P/S (Price to Sales ratio):
$12.24
-0.590933757
P/B (Price to book value ratio):
Price to sales ratio is -59.09% below the industry mean
-
-
Net income growth rate (3Y):
Annual revenue growth rate is -97.57% below industry average
-208.25%
Dividend Analysis
Net income growth rate is -208.25% lower than the industry average net income growth rate
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dividend History:
-
--$0.00
--$0.00
--$0.00
--$0.00
--$0.00
-
In-depth Debt & Leverage Analysis
Debt to equity ratio:
214.01%
Net debt to equity ratio:
The remaining useful life of property plant & equipment is: 0.0 years
Debt to assets ratio:
34.63%
Net debt to assets ratio:
341.68%
42.72%
Ability to repay debt:
Interest coverage ratio:
Debt-to-asset ratio is 42.72% above industry average
-1.17
Looking forward:
Debt growth rate:
2.2x
515.57%
0.10%
Analysis of Key Statistics
Correlation of price movement with the market:
7.270403461
Statistical significance of correlation:
-0.60%
Average Correlation of the industry with the market:
0.268
-42.72%
R Squared (percentage of price movement explained by movement of the market):
0.268
Correlation of price movement with Nasdaq (^IXIC):
0.072
Covariance of price movement with the market:
0.044
Kurtosis
0.11
5.416
Skewness of returns:
Returns have moderate fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns
-0.269
Fundamental Analysis & Dupont Analysis of
Medical Devices
Gross Profit Margin Ratio:
137.18M
Operating Profit Margin Ratio:
Net profit margin is -68.91% lower than the industry
-69.47%
Net Profit Margin Ratio:
137.18M
Effective Tax Rate:
-31.78%
-1.206885449
Dupont Method
Net Profit Margin
Return on Equity Ratio (ROE):
×
ROA
=
×
Return on assets (ROA) is 41.49% higher than the industry
200.62%
Financial Leverage
Asset Turnover Ratio (ROA):
Operating profit margin is -69.47% lower than the industry
41.49%
Financial Leverage:
Interest coverage ratio is -116.71% less than industry average
Current Ratio:
Return on equity (ROE) is 200.62% higher than the industry
-0.50528643
Cash Conversion Cycle (days):
$7.53
0.012973641
Current ratio is -50.53% below industry average
Stock based compensation to net income ratio:
-
In-depth Efficiency Analysis
Revenue generated per employee:
Cash conversion cycle is 1.30% above industry average
0.379125784
EBITDA generated per employee:
Each employee generates 38% more revenue than industry average revenue per employee
-3.39667764
Profit generated per employee:
-$0.35
-7%
Free cash flow (FCF) generated per employee:
Each employee generates -7% less net income/profit than industry average revenue per employee
3.570006661
Assets/Capital per employee
Each employee generates 357% more free cash flow than industry average revenue per employee
3.570006661
Research & Development (R&D) Analysis
50.59%
-386.8363485
Competitors/Peer firms of
Medical Devices
$83.75
Collegium Pharmaceutical, Inc. (XNAS:COLL)
IMAGO BIOSCIENCES, INC. (XNAS:IMGO)
ABSCI CORPORATION (XNAS:ABSI)
BLUEBIRD BIO, INC. (XNAS:BLUE)
CAREMAX, INC. (XNAS:CMAX)
Precigen, Inc. (XNAS:PGEN)
Surmodics, Inc. (XNAS:SRDX)
EAGLE PHARMACEUTICALS, INC. (XNAS:EGRX)
Current Analyst Ratings
-$0.79
Strong buy�4%
Buy�8%
Hold�4%
Sell�0%
Strong sell�0%
Income Statement
Period:
3/31/2022
Date:
Value
Revenue:
TTM
Cost of Revenue:
Gross Profit:
R&D Expense
General & Admin Expenses:
Selling, General & Admin Expenses
Sales and Marketing Expenses
Other Expenses :
Operating Expenses :
Cost & Expenses :
Interest Income:
Interest Expenses:
Depreciation & Amortization:
EBITDA:
Operating Income:
Other Income Expenses:
Income Before Tax:
Income Tax Expense:
Net Income:
Balance Sheet
Date:
Calendar Year:
Period:
Cash & Cash Equivalents:
Short Term Investments:
Cash & Short Term Investments:
Net Receivables:
Inventory:
Other Current Assets:
Total Current Assets:
PP&E:
Goodwill:
Intangible Assets:
Long Term Investments:
Tax Assets:
Other Non-Current Assets:
Total Non-Current Assets:
Other Assets:
Total Assets:
Accounts Payable:
Short Term Debt:
Tax Payables:
Deferred Revenue:
Other Current Liabilities:
Total Current Liabilities:
Long Term Debt:
Other Non-Current Liabilities:
Total Non Current Liabilities:
Other Liabilities:
Total Liabilities:
Common Stock:
Retained Earnings:
Accumulated Other Comprehensive Loss:
Other Total Stockholders' Equity:
Total Stockholders' Equity:
Total Liabilities and Stockholders' Equity:
Total Investments:
Total Debt:
Net Debt:
239.62M
102.43M
229%
23.96M
39.08M
125.72M
86.64M
-
252.11M
-
3.10M
1.41M
-12%
1.30M
1.07M
-19%
1.30M
Statement of Cash Flow
Date:
Period:
- 15142.00K
Differed Income Tax :
427.00K
Stock Based Compensation :
41.00K
Change in Working Capital :
4.04M
Accounts Receivables:
- 20408.00K
Other Working Capital:
5.76M
Other Non-Cash Items:
239.00K
Net Cash Provided by Operating Activities:
1.44M
Investments in PP&E:
- 29604.00K
Net Acquisitions:
- 321.00K
Purchases of Investments:
-
Sales/Maturities of Investments:
Other Investing Activities:
Net Cash Used for Investing Activities:
Debt Repayment:
Common Stock Issued:
Common Stock Repurchased:
Dividend Paid:
Other Financing Activities:
Net Cash Used Provided by Financing Activities:
Effect of FOREX on Changes in Cash:
Net Changes in Cash:
Cash at End of Period:
Cash at Beginning of Period:
Operating Cash Flow:
Capital Expenditure:
Free Cash Flow (FCF):
Value
3/31/2022
2022
Q1
57.73M
74.05M
131.78M
33.17M
51.68M
20.16M
236.78M
17.34M
1.34M
-
-
737.00K
10.49M
29.91M
-
266.69M
13.65M
2.63M
9.85M
9.72M
48.04M
74.04M
147.47M
680.00K
149.49M
-
223.53M
18.00K
- 73315.00K
- 11.0K
Value
149.68M
-
43.16M
266.69M
-
150.10M
- 74058.00K
-
-
- 74379.00K
- 150.00K
-
-
-
- 2299.00K
- 2449.00K
-
- 106432.00K
58.43M
164.86M
- 29604.00K
- 321.00K
Our Proprietary Portfolio Rating
Our Rating:
-223.3038669
Price Forecast/Expected Price in Next 5 Years of
Medical Devices
2023
2024
2025
2026
2027
52.5344418
$52.53
$59.03
$66.33
$74.54